Holen Sie sich die Stockscreener-App
1.34
10.67%
-0.16
Reviva Pharmaceuticals Holdings Inc Aktie (RVPH) Neueste Nachrichten
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World
Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire
Reviva Announces Proposed Public Offering - GlobeNewswire
Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan
Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks
Reviva Announces Positive Preliminary Topline Data for the - GlobeNewswire
Reviva's Brilaroxazine Shows Promising Long-Term Results in Phase 3 Schizophrenia Trial - StockTitan
Reviva Pharmaceuticals Holdings, Inc. Holds Annual Meeting and Approves Increase in Authorized Shares - Defense World
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha
Analyzing Reviva Pharmaceuticals (NASDAQ:RVPH) and Akebia Therapeutics (NASDAQ:AKBA) - Defense World
RVPH: Year-End OLE Update - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com
Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Pharma: 108 Patients Complete 1-Year Schizophrenia Drug Trial as Losses Narrow | RVPH Stock News - StockTitan
Reviva reports progress in schizophrenia treatment study By Investing.com - Investing.com Australia
Reviva reports progress in schizophrenia treatment study - Investing.com
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire
Reviva's Brilaroxazine Hits Key Milestone: 108 Patients Complete 1-Year Schizophrenia Trial | RVPH Stock News - StockTitan
Reviva to Present Positive Speech Latency Data for - GlobeNewswire
Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit | RVPH Stock News - StockTitan
Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewswire
Reviva To Report Long-Term Safety Data For Brilaroxazine In Schizophrenia: Will The Stock Recover? - RTTNews
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst - Benzinga
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times
CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports
RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex
RVPH: RECOVER Biomarker KOL Event - Yahoo Finance
Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex
A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News
Reviva reports positive schizophrenia trial results - Investing.com India
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire
How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):